The great thing about working at Miraca Life Sciences is that we’re constantly evolving and ﬁne tuning our approach to cases. We are focused on pushing the envelope with testing for diseaseslike paroxysmal nocturnal hemoglobinuria (PNH). We also want to contribute to the knowledge base of cliniciansthrough the practice ofsuperior hematopathology methods guided by clinical reason and patient presentation.
With the advent of therapy for PNH, there has evolved a focus on identifying smaller and smaller subpopulations of PNH clones. Some patients with myelodysplasia and aplastic anemia have minute PNH clones. The signiﬁcance of these clones is unclear in the context of PNH or myelodysplastic syndromes(MDS). However, there are preliminary data suggesting there are implicationsfor therapy of MDS patients with such clones. But ultimately, the signiﬁcance will be determined through the observation of patient outcome. The complete service that is the hallmark of Miraca Life Sciences Hematopathology and the Miraca Life Sciences Registry will feed directly into studies that will aid in these discoveries.
The Miraca Life Sciences Registry maintains detailed molecular proﬁling information and hematopoietic diagnostics about a participating patient’s disease, treatment plan and response. This provides an opportunity for physicians and their patients to contribute to the future of individualized care. The information gathered by the registry will be an important factor in discovering what a 0.01 percent PNH clone means for a patient with myelodysplasia or aplastic anemia, just to name a single example.
When I joined Miraca Life Sciences, I really wanted to be a part of an entity that is growing from a service perspective. We have our own molecular testing, cytogenetics with FISH, IHC staining and top end ﬂow cytometry. This allows us to bring a level of service that is unparalleled. Our expert laboratorians keep us apprised of the best methods for detection of various abnormalities. We therefore have the ability to educate the clinician as to why we perform the tests we do and do not perform. As a hematopathologist this is extremely appealing. We can service a broad range of clinicians and through the Miraca Life Sciences Registry, we can help our clinicians and their patients contribute to the future of oncologic medicine.
I hope that you’ll read this issue of The Diﬀerential, which contains information about PNH and how Miraca Life Sciences is setting a standard for the diagnosis of this disorder. I hope it also reﬂects the evolving nature of the Miraca Life Sciences laboratories as we continually strive to improve hematopathology services for our clinicians and their patients.